Methods
This multicenter, observational study included ≥18 year-old NVAF patients from August 2012 through November 2013. Patients with cognitive disorders, postoperative NVAF, or NVAF due to reversible causes, those having myocardial infarction or undergoing any operations within the last 3 months, those participating in another clinical trial in the last 6 months, and pregnant or breastfeeding females were excluded. Bleeding-related risk factors were assessed using the HAS-BLED scores at baseline, 6th month, and 12th month. For categorical variables, Pearson chi-square test was used in two group comparisons.
Methods
This multicenter, observational study included ≥18 year-old NVAF patients from August 2012 through November 2013. Patients with cognitive disorders, postoperative NVAF, or NVAF due to reversible causes, those having myocardial infarction or undergoing any operations within the last 3 months, those participating in another clinical trial in the last 6 months, and pregnant or breastfeeding females were excluded. Bleeding-related risk factors were assessed using the HAS-BLED scores at baseline, 6th month, and 12th month. For categorical variables, Pearson chi-square test was used in two group comparisons.
Results
The median age of the patients (n=210; males, 57.1%) was 65 years (range, 20-88 years). Of the patients, 61.4% were inpatient. Among the patients, 43.8% had permanent AF, 32.9% had paroxysmal AF, and 23.3% had persistent AF. At baseline, 84.3% of the patients were on antithrombotic therapy.
The HAS-BLED scores were 0-2 and ≥3 in 83.1% and 16.9% of the patients, respectively. Bleeding was observed in 22.6% (n=33) and 25.0% (n=35) of the patients at the 6th and 12th months, respectively. The rate of major bleeding was 5.5% at the 6th month and 7.1% at the 12th month. Table 1 demonstrates the HAS-BLED scores and bleeding in the drug groups.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
